94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Tianyi Bu1†
Jiarun Yang2†Jiawei Zhou1†Yeran Liu3Kexin Qiao1Yan Wang1Jili Zhang1Erying Zhao1Boakye Kwame Owura1Xiaohui Qiu1*Zhengxue Qiao1*
Yanjie Yang1*- 1Psychology and Health Management Center, Harbin Medical University, Harbin, China
- 2Department of Psychology, School of Education of Heilongjiang University, Harbin, China
- 3School of Humanities, Harbin Medical University, Harbin, China
Introduction: As a common and complex mental disorder, major depressive disorder (MDD) has brought a huge burden and challenges globally. Although the incidence of female MDD is twice that of male MDD, there are still no accurate diagnostic and treatment criteria for female MDD. The potential of long non-coding RNAs (lncRNAs) as efficient and accurate diagnostic and therapeutic biomarkers provides more possibilities for early and accurate diagnosis of MDD.
Methods: First, the differential expression profile of lncRNAs in peripheral blood mononuclear cells (PBMCs) between MDD patients and healthy controls was established based on high-throughput sequencing analysis. Then, the potential biomarker was screened out by quantifying differentially expressed lncRNAs based on quantitative real-time PCR. To further investigate the function of biomarkers in the pathogenesis of MDD, bioinformatics analysis on downstream target genes was carried out.
Results: The expression profile screened out 300 differentially expressed lncRNAs. HYMAI was proved to be the potential diagnostic biomarker. Its expression levels were significantly higher in MDD patients than in healthy controls with high potential diagnostic value. Based on bioinformatics analysis, a HYMAI–miRNA–mRNA network and a protein–protein interaction network were established, which also showed that HYMAI is closely related to MDD.
Discussion: Our findings showed that the dysregulated expression of lncRNA HYMAI may be the pathophysiological basis of women suffering from MDD. Here, insight into the molecular mechanism of women’s susceptibility to MDD is shown. Meanwhile, a new perspective for future female MDD prevention, diagnosis and treatment, evaluation, detection, and intervention is provided.
1 Introduction
Major depressive disorder (MDD) is a common and complex mental disorder with a considerable morbidity rate. It is one of the main causes of disability, disease burden (1), and suicide deaths globally (2, 3). A large-scale longitudinal study has illustrated that MDD increases people’s risk of suffering from other chronic diseases, cancer, and other mental diseases (4). At present, the criteria for the diagnosis and treatment of MDD are mainly based on the signs and symptoms of the diagnosis category. Meanwhile, the diagnostic outcome and treatment plan still depend on the subjective evaluation of the psychiatrists’ clinical experience. Due to the heterogeneity and the unclear evaluation boundary of MDD, MDD is difficult to be accurately diagnosed (5, 6). The assessment of the severity of MDD based on patient symptoms is not accurate enough; as a result, a considerable number of MDD patients fail to receive appropriate treatment, develop resistance to treatment, and have a high recurrence rate (7, 8). Therefore, there is an urgent need to clarify the pathogenesis of MDD and explore efficient, objective, and precise diagnostic and therapeutic biomarkers so as to provide more possibilities for early diagnosis and precise treatment of MDD.
The pathogenesis of MDD needs to be further explored. Previous studies have illustrated that MDD is a multifactorial disorder with multiple neurobiological hypotheses, involving imbalances in levels of monoamine neurotransmitters (dopamine, serotonin, and norepinephrine) in the brain, alterations in neuroplasticity (neurogenesis and synaptic plasticity), dysregulation of the immune system, and the involvement of specific brain regions (the prefrontal cortex, hippocampus, and amygdala) (9, 10). The involvement of epigenetic mechanisms gains increasing attention. Recent advances in gene regulation through epigenetic mechanisms suggest that its regulation of the genome is far beyond what was originally thought (11). Epigenetic factors may not only contribute to the pathogenesis of MDD but may also affect an individual’s response to medication (12). Long non-coding RNA (lncRNA) is a transcript with a length of more than 200 nucleotides and plays a complex regulatory role in gene expression in the form of RNA at the transcriptional, post-transcriptional, and epigenetic levels (13, 14). It has been considered to be the most complex and diverse RNA with functions and types discovered so far, and its quantity is basically the same as the quantity of messenger RNA (mRNA) (14, 15). It is well documented that lncRNAs have taken part in different stages of brain development and its activity, such as being involved in synaptogenesis (16), synaptic plasticity (18), neurogenesis (16), neuron development (17), and maintenance of proper nervous system functioning (18). LncRNA may play a crucial role in the etiology of neurological and psychiatric diseases. Previous studies have shown that epigenetic changes can alter the function and structure of neurons in some way, thereby participating in the occurrence and development of MDD (19). A review of the link between lncRNA and MDD suggests that lncRNA may be the most promising new biomarker for MDD and has the potential to be a therapeutic target (20).
Numerous studies have shown that lncRNA is involved in various key epigenetic regulatory processes and thus participates in the occurrence and development of diseases. According to the competitive endogenous RNA (ceRNA) hypothesis, ceRNA competitively binds microRNA (miRNA) through miRNA response elements (MREs); thereby, the regulation of miRNAs on their target genes will be affected (21). As a ceRNA, the regulatory role of lncRNA has been widely explored in various diseases, such as cancer (22), osteoarthritis (23), diabetes (24), and myasthenia gravis (25). However, very few studies have explored the ceRNA mechanism of lncRNA in MDD. Barry suggested that lncRNAs present as critical regulators in the evolution of higher brain functions (26). Previous studies have also emphasized that 30% of differentially expressed genes in patients with MDD were lncRNAs (27). All lines of evidence showed that the molecular mechanism of the role of dysregulated lncRNAs in MDD needs further investigation.
As we all know, women are twice as likely to suffer from MDD compared with men (28), with higher severity of symptoms, more severe dysfunction, less typical depressive symptoms, and a higher rate of co-morbid anxiety (29). Functionally, the brains of men and women with MDD observe different amplitude, laterality, and volume changes (30). Meanwhile, the responses to the treatment vary with gender (29, 31). However, the molecular mechanisms contributing to this sex difference remain poorly understood till now. Labonté et al. exhibited the transcriptomes of six brain regions of MDD and healthy persons based on RNA-sequencing analysis (32). The result showed that MDD is characterized by strong sexual dimorphism due to hardly any overlap between male and female MDD differential transcripts. Based on the above dataset, Issler et al. carried out a further analysis and pointed out there is a sex-specific regulatory influence of lncRNAs on gene expression (27). Zhou et al. showed that the regulatory influence of lncRNAs on gene expression was stronger in women than men (33). All these findings revealed that male and female MDD may be derived from different genetic changes. In other words, the pathogenesis of MDD is not the same between men and women. It is necessary to explore the pathogenesis of MDD on a gender-specific basis. To summarize, women are a group with a high incidence of MDD, and the pathogenesis not only should be paid more attention but also needs to be explored separately.
The purpose of this study was to explore potential diagnostic biomarkers of female MDD and then investigate its regulatory role in female MDD pathogenesis and development. First, high-throughput sequencing analysis was utilized in three paired female MDD patients and healthy controls (HCs) in order to establish a peripheral blood mononuclear cells (PBMCs) lncRNA expression profile. In addition, five differentially expressed candidate lncRNAs were chosen to evaluate the expression level through quantitative real-time PCR (qRT–PCR) for potential MDD diagnostic biomarker validation (MDD, n = 20; HCs, n = 20) as the preliminary verification step. Subsequently, potential biomarkers with high diagnostic value were selected for further verification in the larger cohorts (MDD, n = 70; HCs, n = 70). Finally, to better explain its diagnostic and therapeutic value, bioinformatics analysis was utilized on validated biomarkers to explore its potential function in the pathogenesis of female MDD.
2 Methods
2.1 Study subjects
A total of 73 female patients who met the MDD criteria admitted to the First Psychiatric Hospital of Harbin, Harbin, China, between March 2018 and June 2019 were recruited. The diagnosis was independently given by two psychiatrists subject to the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), based on the structured interviews. The 73 HCs who had undergone physical examination during the same period, matched for MDD patients’ age, gender, and ethnicity, were enrolled. In addition, using the 32-item Hypomania Checklist (HCL-32), all the participants were assessed in order to rule out the participants who had previous episodes of mania or hypomania. All the participants who were included in this study met the criteria, as follows: 1) Han ethnicity, 2) age range of 18–60 years, 3) either first-time visitors or had not received any clinical treatment or intervention at least three months, 4) elementary school education or above, 5) without other physical or neurological diseases (such as cardiopathy, diabetes, or Parkinson’s disease), 6) without history of alcohol or drug abuse, 7) without family history of neuropsychiatric disorders, and 8) currently were not in puberty, perimenopause, or pregnancy. The study was approved by the Ethical Committee of Harbin Medical University. All participants provided signed informed consent forms.
2.2 Blood sample collection
After overnight fasting, 5 mL of peripheral blood was collected using ethylenediaminetetraacetic acid (EDTA) anticoagulant vacutainers and then centrifuged within 2 hours. The PBMCs were separated from the peripheral blood by density-gradient centrifugation over a human peripheral blood lymphocyte separator according to the manufacturer’s protocol.
2.3 RNA extraction in PBMCs
Total RNA was lysed from all the samples with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. Three PBMCs samples from the MDD group were randomly collected, and paired three age-, gender-, and ethnicity-matched HCs were prepared for later high-throughput sequencing analysis. All the other samples were frozen at −80°C for later use. NanoDrop ND-2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) was used for evaluating RNA concentration. Afterward, all the qualified RNAs were reverse-transcribed into complementary DNA (cDNA) using ReverTra Ace qPCR RT Master Mix (TOYOBO, Osaka, Japan) according to the manufacturer’s instructions and then frozen at −80°C for further qRT–PCR.
2.4 High-throughput sequencing analysis
To investigate the expression profile of lncRNAs in MDD, three MDD patients and three matched HCs were analyzed by high-throughput sequencing. Above all, sample concentration and quality testing of PBMCs samples were performed using NanoDrop and Agilent 2100 Bioanalyzer. The sample starting amount needed to reach m ≥ 5 μg, and the sample quality needed to reach c ≥ 200 ng/200 ng/μL and RIN ≥ 7.0 28S/18S ≥ 1.0. Then, the RNase H kit was utilized to remove ribosomal RNA, and the reaction system was configured for RNA fragmentation. Furthermore, the pre-prepared first-strand synthesis reaction mixture was added to the fragmented RNAs in order to synthesize first-strand cDNAs, and then the second-strand synthesis reaction was configured for second-strand cDNA synthesis. After the reaction system and program were configured and set up, double-stranded cDNA fragments were subjected to end-repair, and then a single “A” nucleotide was added to the 3′ ends of the blunt fragments. The reaction system and program for adaptor ligation were subsequently configured and set up to ligate adaptors with the cDNAs. The PCR system was configured to amplify the product. Moreover, the corresponding library quality control protocol was selected depending on product requirements. The fragment range and concentration were detected and quantified using the Agilent 2100 Bioanalyzer and ABI StepOnePlus 156Real-Time PCR System (TaqMan Probe), respectively. Finally, sequencing was performed on the Hiseq 4000 or Hiseq X-ten platform (BGI-Shenzhen, Shenzhen, China). Single-stranded circle DNA molecules were replicated via rolling circle amplification, and a DNA nanoball (DNB), which contains multiple copies of DNA, was generated. Sufficient quality DNBs were then loaded into patterned nanoarrays using a high-intensity DNA nanochip technique and sequenced through combinatorial probe-anchor synthesis (cPAS). The differentially expressed lncRNAs (DElncRNAs) of the HCs group and the MDD group were analyzed using the R studio (V4.0.4) DESeq package. Those that reached Q-values < 0.01 and |log2FC| > 1 were differential lncRNAs, where those with log2FC > 1 were marked as upregulated lncRNAs and those with log2FC < −1 were marked as downregulated lncRNAs, and those that do not meet the above conditions were not DElncRNAs.
2.5 Quantitative real-time PCR analysis
The candidate DElncRNAs were quantified by qRT–PCR using the Roche LightCycler 480II system (Roche Diagnostics, Basel, Switzerland). The reaction conditions implemented were as follows: denaturation at 95°C for 10 min and 40 cycles of amplification including 95°C for 10 s, 55°C for 10 s, and 72°C for 10 s. All qRT–PCRs were performed in triplicate. Human β-actin was selected for normalizing RNA relative expression level. The expression levels of each lncRNA were calculated by the 2−ΔΔCt method. The ΔCt value equaled the average of each target lncRNA Ct value minus the β-actin Ct value in corresponding samples.
2.6 Bioinformatics analysis
2.6.1 Prediction of lncRNA–miRNA–mRNA network
The algorithm DIANA-LncBase v3.0 (https://diana.e-ce.uth.gr/lncbasev3) was applied to predict the target miRNAs of the previously verified lncRNA. The potential targets of these selected microRNAs were predicted using the bioinformatics tool ENCORI (The Encyclopedia of RNA Interactomes; http://starbase.sysu.edu.cn/index.php), miRDB (http://mirdb.org/), miRWalk 3 (Http://mirwalk.umm.uni-heidelberg.de/), TargetScan 7.2 (http://www.targetscan.org/vert_72/), and miRPathDB v2.0 (https://mpd.bioinf.uni-sb.de/overview.html). In order to obtain the intersection of target genes in each database to enhance the reliability of the predicted, Venn diagrams were calculated and drawn using the tool Bioinformatics & Evolutionary Genomics (http://bioinformatics.psb.ugent.be/webtools/Venn/). The constructed lncRNA–miRNA–mRNA network was visualized using the Cytoscape software (V.3.8.2).
2.6.2 GO and KEGG pathway enrichment analysis
In order to exhibit the potential function of the predicted target genes more comprehensively, the Gene Ontology Resource (GO) (http://geneontology.org/) function annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) (https://www.kegg.jp/kegg/) pathway enrichment analysis of target genes were carried out using DAVID 6.8 (https://david.ncifcrf.gov/). GO function annotation provides an interpretation of target gene function from the following three aspects: molecular functions of gene products, the cellular environment they are located in, and the biological processes. The terms were screened out with p < 0.05, which showed significantly enriched functions.
2.6.6 Construction PPI network and module analysis
To further illuminate the function of predicted genes in the ceRNA network, a protein–protein interaction (PPI) network was established using Search Tool for the Retrieval of Interacting Genes (STRING Version 11.0; https://string-db.org/). In the Cystoscope software, the Molecular Complex Detection (MCODE) plug-in was used for gene cluster classification, and the CytoHubba plug-in was used for hub gene filtering. At last, the PPI network was constructed and visualized using the Cytoscape software (V.3.8.2).
2.7 Statistical analysis
Volcano plot and heat map were visualized using differentially expressed genes with the ggplot2 package in R version 4.0.3. All statistical analyses were conducted using the GraphPad 8 software (Version 8.0.2; GraphPad Software, La Jolla, CA, USA) and R software (Version 4.0.3). Data distributions were assessed by the Shapiro–Wilk test. If the p-value was greater than 0.05, the data were considered to be in a normal distribution; otherwise, the data were considered to be non-normal. The differences in the expression levels of lncRNAs among patients with MDD and HCs were assessed using a t-test if the data were normally distributed. Otherwise, the Mann–Whitney U test was used. Findings with p < 0.05 results were considered statistically significant. To evaluate the diagnostic value of the DElncRNAs, a receiver–operator characteristic (ROC) curve was established. The evaluation of diagnosis ability depended on the area under the ROC curve (AUC). In the case of AUC > 0.5, the closer the AUC value was to 1, the better the diagnostic effect.
3 Results
3.1 Identification of lncRNA expression profile
Based on high-throughput sequencing analysis, the full expression profile of lncRNAs in PBMCs between two groups was established. On account of threshold |log2FC| > 1 and Q-value < 0.01 criteria, there were 300 DElncRNAs screened, of which 128 were upregulated and 172 were downregulated as shown in the heat map and volcano plot (Figures 1A, B). Afterward, five candidate lncRNAs were chosen for further validation in order to investigate the potential diagnostic biomarker. The primers for qRT–PCR are listed in Table 1.
Figure 1
Figure 1. (A) Heat map of DElncRNAs associated with MDD. (B) Volcano plot highlighting significantly upregulated (purple) and downregulated (green) lncRNAs. DElncRNAs, differentially expressed lncRNAs; lncRNAs, long non-coding RNAs; MDD, major depressive disorder.
Table 1
Table 1. Primers used for qRT–PCR analysis of lncRNA expression levels.
3.2 Validation of the diagnostic biomarker
The expression levels of DElncRNAs in PBMCs between female MDD patients and HCs were quantified by qRT–PCR. In the preliminary validation step (MDD n = 20, HCs n = 20), the levels of HYMAI and LOC107987438 expression were significantly higher in patients with MDD than in healthy controls (Figure 2A). The diagnostic values of these two candidate biomarkers were evaluated using ROC curves. Based on ROC curve analysis, HYMAI presented a better diagnostic value because of the larger AUC (AUC = 0.915, 95% CI: 0.834–0.996, p < 0.05) compared to LOC107987438 (AUC = 0.698, 95% CI: 0.531–0.864, p = 0.097) (Figure 2B). To further determine the actual diagnostic value of HYMAI, a larger cohort qRT–PCR was carried out. In the further validation step, the expression of lncRNA HYMAI remained significantly different. The expression levels of lncRNA HYMAI were significantly higher in patients with MDD than in HCs (Figure 3A). The AUC of lncRNA HYMAI was 0.867 (95% CI: 0.809–0.925, p < 0.0001), suggesting it has a high potential diagnostic value (Figure 3B).
Figure 2
Figure 2. The differential expression levels and ROC curves of DElncRNAs in PBMCs between MDD patients (MDD, n = 20) and healthy controls (HCs, n = 20) by qRT–PCR. (A) The expression of HYMAI and LOC107987438 in MDD was significantly higher than that in HCs. *p < 0.05,***p < 0.001. (B) ROC curve analysis of HYMAI, LOC107987438, LOC105377781, LOC105373656 and LOC107987461. ROC, receiver operating characteristic; DElncRNAs, differentially expressed long non-coding RNAs; PBMCs, peripheral blood mononuclear cells; MDD, major depressive disorder.
Figure 3
Figure 3. (A) The differential expression levels of lncRNA HYMAI in PBMCs between two groups (MDD, n = 70; HCs, n = 70). HYMAI expression level was increased in MDD group compared with HCs group, as determined by qRT–PCR. ****p < 0.0001. (B) The ROC curves of lncRNA HYMAI in PBMCs of MDD group. The area under the ROC curve was 0.867. lncRNA, long non-coding RNA; PBMCs, peripheral blood mononuclear cells; MDD, major depressive disorder; ROC, receiver operating characteristic.
3.3 Interaction of lncRNA–miRNA–mRNA
A total of nine miRNAs were predicted to target HYMAI by LncBase: hsa-miR-139-5p, hsa-miR-17-5p, hsa-miR-19a-3p, hsa-miR-19b-3p, hsa-miR-221-3p, hsa-miR-23a-3p, hsa-miR-28-5p, hsa-miR-33a-5p, and hsa-miR-23b-3p. Among these nine miRNAs, only hsa-miR-23b-3p presents low miRNA confidence. To further examine the potential downstream pathway, the remaining eight high-confidence miRNAs were selected to predict target genes. The target genes after taking the intersection were displayed in the Venn diagram (Figure 4). A total of 897 target genes harbored the above eight miRNAs. Subsequently, the constructed lncRNA HYMAI–miRNA–mRNA network map is presented in Figure 5. hsa-miR-23a-3p exhibited the largest interaction network.
Figure 4
Figure 4. Venn diagram of the predicted miRNA target genes. miRNA, microRNA.
Figure 5
Figure 5. ceRNA network of lncRNA HYMAI–miRNA–mRNA in female major depressive disorder. The network consists of 1 lncRNA node, 8 miRNA nodes, and 897 mRNA nodes. Orange color indicates lncRNA, green color presents miRNA, and purple color illustrates mRNA. lncRNA, long non-coding RNA; miRNA, microRNA; ceRNA, competitive endogenous RNA; mRNA, messenger RNA.
3.4 GO and KEGG pathway enrichment analysis
GO function annotations and KEGG pathway analysis were carried out for the target genes. Out of the GO function annotations indicated among the 214 biological process terms, the highest enriched terms were “transcription, DNA-templated“, “regulation of transcription, DNA-templated“, and “positive regulation of transcription from RNA polymerase II promoter“ (p < 0.05). In terms of cellular components, the target mRNAs were most enriched in terms of “cytoplasm”, “nucleus“, and “cytosol“ (p < 0.05). For molecular function, the enriched terms were “protein binding“, “metal ion binding“, and “metal ion binding“ (p < 0.05) (Figure 6). According to the result of the KEGG pathway analysis, 34 pathways were significantly enriched, such as “FoxO signaling pathway“, “mTOR signaling pathway“, “MAPK signaling pathway“, “Wnt signaling pathway“, “Neurotrophin signaling pathway”, and “Insulin resistance”. The top 20 enriched pathways are shown in Figure 7.
Figure 6
Figure 6. GO function annotations of downstream target genes. The green bar chart illustrates the biological process, the purple car chart expounds the cellular component, and the gray bar chart illustrates the molecular function. GO, Gene Ontology.
Figure 7
Figure 7. KEGG pathway analysis of the downstream target genes. KEGG, Kyoto Encyclopedia of Genes and Genomes.
3.5 Construction PPI network and module analysis
Based on the String database, a PPI network with 800 nodes and 2977 edges was established, which is too huge to show the specific information. The divided module was identified by MCODE from the PPI network. The significant module related to MDD contained 27 nodes and 89 edges, as shown in Figure 8. Next, the top 10 hub genes were screened out using CytoHubba based on the Maximal Clique Centrality (McC) method. They were SNAI2, GSK-3β, DVL1, FZD5, THBS1, VANGL1, RUNX1, COL4A1, TGFβ2, and REST.
Figure 8
Figure 8. The selected cluster of protein–protein interaction network identified by MCODE was visualized using Cytoscape v.3.6.1. The size of node depends on significance of p-value. The more significant p-value, the larger the diameter of node. The color of the edge represents the value of combined score from 0.4 to 1, light to dark.
To sum up, we found that there were a large number of DElncRNAs between the PBMCs of female MDD patients and HCs. HYMAI was validated to have the potential to be a diagnostic and therapeutic biomarker. Based on bioinformatics analysis, a HYMAI–miRNA–mRNA network was established, which also showed that HYMAI is closely related to MDD. Moreover, protein–protein interaction analysis screened out 10 hub genes, which provided the possibility for us to further interpret the mechanism of HYMAI in female MDD.
4 Discussion
This study attempted to present a more comprehensive understanding of female MDD pathogenesis. Epigenetic mechanisms as the basis for gene regulation are ideal for studying MDD. At present, little is known about the potential role of lncRNA as a diagnostic and therapeutic biomarker, and there are few studies evaluating the clinical value of lncRNA in efficacy as well. In order to better explore the mechanism of action of lncRNA regulation in MDD, a female-specific lncRNA expression profile in PBMCs between MDD and HCs was established based on high-throughput sequencing analysis. Most previous studies have only explored the differential expression of lncRNA in female MDD patients and HCs based on microarray analysis. In this study, the expression profile of lncRNA was constructed based on high-throughput sequencing, which not only found more novel lncRNA but also laid a foundation for the molecular mechanism study of female MDD. Undoubtedly, for the diagnosis and treatment of MDD, the screening of potential diagnostic markers of MDD by DElncRNA expression profiling based on PBMCs has shown good clinical application value.
As well known, there is no objective physiological and biochemical indicator for MDD, which brings great trouble to the accurate diagnosis and treatment of MDD. Our study explores this question and verifies that lncRNA HYMAI in PBMCs could be the potential diagnostic biomarker for female MDD. MDD peripheral blood biomarkers have incomparable advantages in the application of clinical diagnosis. The discovery of female MDD biomarker lncRNA HYMAI in PBMCs may have some application prospects in the future to help researchers accurately diagnose, monitor treatment response, detect intervention effects, or detect early recurrence in real time. In our previous study, we found that circRNA hsa_circ_0126218 has the potential to become a biomarker of female MDD (34). Compared with previous findings, a higher potential diagnostic value has been shown by lncRNA HYMAI, which suggested that lncRNA HYMAI is more likely to become a biomarker of female MDD. It has been investigated in several fields. Arima et al. suggested that HYMAI as an imprinted gene may participate in transient neonatal diabetes mellitus (35, 36). Another study pointed out that imprinted expression of HYMAI in skin fibroblasts is tight in healthy individuals but not in transient neonatal diabetes mellitus patients (37). Even though HYMAI has been found over-expressed in transient neonatal diabetes mellitus patients, the function of this transcript is still unclear. Thereby, another study was carried out for a deeper interpretation of its molecular mechanism. The study showed that HYMAI may interact with chromatin machinery to protect paternal alleles from DNA methylation (38). More than that, there is also a close link between altered methylation levels at PLAGL1/HYMAI differentially methylated regions and high-risk human papillomavirus infections (39). Ryan et al. indicated that HYMAI expression in the whole blood of patients who acquired chronic inflammatory response syndrome following an exposure to the marine toxin ciguatoxin was significantly upregulated (40). The upregulated HYMAI may also be considered the potential biomarker for endothelial hypoxia in human atherosclerotic lesions (41). A recent study expounded that HYMAI as an autophagy-related lncRNA may play a complex function and could be considered a favorable prognostic factor in acute myeloid leukemia progression (42). In clear cell renal cell carcinoma patients, HYMAI expression has also been found to be associated with overall survival (43). Previous studies have shown that MDD is common among kidney cancer patients (44, 45), atherosclerotic lesion patients (46), diabetes patients (47), acute myeloid leukemia patients (48, 49), and human papillomavirus infection patients (50). There is also a certain correlation between diabetes and coronary artery disease atherosclerotic plaque characteristics (51). Thus, it can be concluded that HYMAI may share genetic vulnerability contributing to the link between MDD and other diseases. Meanwhile, it is also indicated that lncRNA HYMAI could be a potential intervention target for MDD in the future.
As mentioned above, due to the unclear pathogenesis of MDD, there is no effective antidepressant medication, resulting in a high rate of medicine resistance or recurrence. To further interpret the molecular mechanisms of elevated HYMAI in the pathologies of female MDD, bioinformatics analysis was utilized. The established HYMAI–miRNA–mRNA, which provides an intuitive way to analyze the downstream pathway, could promote further analysis of the role of HYMAI in the pathogenesis of MDD. As mentioned above, a total of eight miRNAs with high confidence have been taken into account in the ceRNA network. Four of them (hsa-miR-221-3p, hsa-miR-139-5p, hsa-miR-17-5p, and hsa-miR-19a-3p) have been reported to be closely linked with MDD. A previous study found that the relative expression levels of miR-221-3p, miR-33a-5p, and miR-139-5p in the cerebrospinal fluid of MDD patients were significantly higher than those in HCs based on the microRNA PCR panel analysis. Among them, miR-221-3p may be a potential biomarker for MDD due to its dysregulation in both the cerebrospinal fluid and serum of MDD patients (52). Meanwhile, the expression of serum miR-221-3p is sensitive to depressed mood in perioperative patients as well (53). Furthermore, upregulated exosome-derived miR-139-5p could cause depressive-like behaviors in mice due to its role in the impairment of adult hippocampal neurogenesis (54). Meanwhile, exosomal miR-139-5p was also considered to be the MDD biomarker on account of its dysregulation in MDD patients (55). The expression of miR-19a-3p in PBMCs was reported to be upregulated in MDD patients with suicidal ideation (46). Carmkurt et al. pointed out that the expression level of hsa-miR-17-5p is upregulated in the plasma of patients with MDD (56). Based on a systematic review and a bioinformatics analysis, Ferrúa et al. illustrated that hsa-miR-17-5p is one of the most frequent miRNAs that take part in MDD-related pathways (57). Despite that the other four RNAs have not been reported, they are also worthy of further verification in subsequent studies. Due to the large number of predicted downstream target genes, bioinformatics analysis will be used to further clarify the regulatory network that is more likely to play a role in the pathogenesis of MDD.
The result of target gene function annotation and enriched analysis illustrated that the altered HYMAI is engaged in affecting some important genes and pathways related to MDD, such as “mTOR signaling pathway“, “MAPK signaling pathway“, “Wnt signaling pathway“, and “Insulin resistance’. The mTOR signaling pathway takes part in synaptic protein synthesis (58). Synaptic deficits caused by abnormal dysregulation of mTOR signaling may play a pivotal role in the pathogenesis of MDD (59, 60). The role of the MAPK pathway in MDD has been widely investigated (61, 62). Accumulating biological evidence indicates that depressive-like behaviors contribute to inhibiting the MAPK pathway (8, 63). It is worth noting that a gender-specific study exploring the role of the Ras–Raf–MAPK signaling pathway in MDD revealed that different haplotypes and gene–gene interactions in the pathway may lead to female patients being more susceptible to antidepressant efficacy compared to male patients (64). The dysregulation of the Wnt signaling pathway can lead to various neurological and neuropsychiatric disorders (65, 66). It is widely known that the Wnt signaling pathway participates in MDD (67, 68), as well as in response to antidepressants (69). The relationship between MDD and insulin resistance has gained more and more attention (70, 71). The synergy of insulin resistance and high levels of stress can increase the susceptibility to MDD (72). The results suggest that HYMAI can participate in MDD pathogenesis by regulating downstream target genes.
The established PPI network presented the interactions between the predicted target genes intuitively. The top 10 hub genes are SNAI2, GSK-3β, DVL1, FZD5, THBS1, VANGL1, RUNX1, COL4A1, TGFβ2, and REST. Some of the genes have been suggested to influence the pathophysiology of MDD (Duda et al., 2020). A recent review showed that the age of onset and severity of MDD are closely related to abnormal GS-3β activity, changes in its expression profile, and genetic polymorphisms. It is not only proposed that GSK-3β is an important factor involved in the pathogenesis of MDD but also pointed out the possibility of GSK-3β as a therapeutic target. A recent study found that the dysregulated miR-128-3p in the amygdala of rats could trigger depressive-like behavior by regulating the downstream target genes (Wnt3, Wnt3a, Wnt5b, Dvl1, and Lef1) involved in the Wnt signaling pathway (73). In addition, DVL1 could encode a cytoplasmic scaffolding protein, which has been implicated in THBS1 antidepressant response in rodents (74). RUNX1 has been clarified to act at multiple levels during the nervous system development (75). Wuchty et al. indicated that RUNX1 as a driver causal gene in MDD may play a crucial role in stress- and trauma-related pathways (76). It has been suggested that REST may be involved in the context of mood disorders and the action of antidepressants based on the analysis of its target genes (69). They also mentioned that the expression level of REST is reduced in MDD patients. These findings will facilitate the investigation of mechanisms of women’s susceptibility to MDD. In our study, the highlighted hub genes in the network will elucidate the mechanism of action of lncRNA HYMAI in the occurrence and development of MDD. In turn, a more accurate strategy for the diagnosis and treatment evaluation of MDD could be provided in the future.
Even though our findings will increase the interpretation of the function of lncRNAs in MDD, some limitations still need to be noticed. First of all, the regulation mechanism of HYMAI has been explained based on the ceRNA hypothesis in this study. However, lncRNAs can also be involved in post-transcriptional regulation through a variety of other mechanisms, including interactions with RNA binding proteins, base pairing with mRNA, and interactions with specific organelles. These mechanisms affect mRNA splicing, stability, translation, and signaling pathways, which regulate gene expression. Other functions of HYMAI based on the role of LncRNA, such as regulating gene expression through interaction with key transcription factors, need to be further explored in MDD. Second, this study only explored female MDD. In subsequent studies, we can construct expression profiles for men and explore the differences in the pathogenesis of MDD between different genders. The reasons why women are more likely to suffer from MDD than men may be elaborated. Moreover, the sample size of this study was 70 pairs. To more powerfully determine the biomarkers, a larger and wider population should be considered in future studies. Furthermore, the samples in this study are mainly from human PBMCs, and the functional research of HYMAI should be further strengthened in cell and animal models in the future. Finally, although this study predicted the pathogenesis of female MDD and found a potential therapeutic target, there is still a need for further experimental studies for verification.
5 Conclusion
In summary, a female-specific lncRNA expression profile in PBMCs between MDD and HCs was established based on high-throughput sequencing analysis, which would provide a basis for sex-specific exploration of the role of lncRNAs in MDD. Through experimental verification, we found that lncRNA HYMAI in PBMCs has the potential to be used as a biomarker of female MDD and has a good clinical application prospect. According to bioinformatics analysis, it is finally clarified that the dysregulated expression of lncRNA HYMAI may be the pathophysiological basis of women suffering from MDD, which provides a more theoretical basis for exploring the pathogenesis of female MDD. Our findings contribute to providing a new perspective for future MDD prevention, diagnosis and treatment, evaluation, detection, and intervention. In the future, the specific molecular mechanism of lncRNA HYMAI in female MDD should be further explored in order to achieve gender-based precise diagnosis and treatment of MDD.
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi.nlm.nih.gov/, PRJNA698421.
Ethics statement
The studies involving humans were approved by Ethical Committee of Harbin Medical University. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.
Author contributions
TB: Writing – original draft, Investigation, Validation, Visualization. JY: Investigation, Formal analysis, Writing – original draft. JWZ: Investigation, Validation, Writing – original draft. YL: Investigation, Formal analysis, Writing – original draft. KQ: Formal analysis, Validation, Writing – original draft. YW: Validation, Data curation, Writing – original draft. JLZ: Data curation, Visualization, Writing – original draft. EZ: Validation, Funding acquisition, Writing – review & editing. BO: Formal analysis. XQ: Writing – review & editing, Supervision. ZQ: Project administration, Resources, Supervision, Writing – review & editing. YY: Conceptualization, Project administration, Writing – review & editing, Funding acquisition, Resources, Supervision.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the General Program of the National Natural Science Foundation of China (81773536) to YY and the Youth Program of the National Natural Science Foundation of China (81903397) to EZ.
Acknowledgments
We would like to express our gratitude to both participants and the psychiatrists who helped to recruit and identify the patients with major depressive disorder in the study.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2025.1241089/full#supplementary-material
References
1. Ferrari A, Charlson F, Pacella R, Patten S, Freedman G, Murray C, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. (2013) 10:e1001547. doi: 10.1371/journal.pmed.1001547
2. Chesney E, And GMG, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry. (2014) 13:153–60. doi: 10.1002/wps.20128
3. Suicide. Available online at: http://www.who.int/topics/suicide/en/ (Accesessed April 29, 2024).
4. Penninx BWJH, Milaneschi Y, Lamers F, Vogelzangs N. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med. (2013) 11:129. doi: 10.1186/1741-7015-11-129
5. Al-Harbi K. Treatment-resistant depression: Therapeutic trends, challenges, and future directions. Patient preference adherence. (2012) 6:369–88. doi: 10.2147/PPA.S29716
6. Lamers F, Vogelzangs N, Merikangas KR, de Jonge P, Beekman ATF, Penninx BWJH. Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol Psychiatry. (2013) 18:692–9. doi: 10.1038/mp.2012.144
7. Nemeroff CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry. (2007) 68 Suppl 8:17–25. doi: 10.1080/13803390701523737
8. Duman CH, Schlesinger L, Kodama M, Russell DS, Duman RS. A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol Psychiatry. (2007) 61:661–70. doi: 10.1016/j.biopsych.2006.05.047
9. Boku S, Nakagawa S, Toda H. amp]]amp; Hishimoto, A:Neural basis of major depressive disorder: Beyond monoamine hypothesis. sychiatry Clin Neurosci. (2018) 72:3–12. doi: 10.1111/pcn.2018.72.issue-1
10. Tartt AN, Mariani MB, Hen R, Mann JJ, Boldrini M. Dysregulation of adult hippocampal neuroplasticity in major depression: pathogenesis and therapeutic implications. Mol Psychiatry. (2022) 27:2689–99. doi: 10.1038/s41380-022-01520-y
11. Barbu MC, Shen X, Walker RM, Howard DM, Evans KL, Whalley HC, et al. Zeng Y et al: Epigenetic prediction of major depressive disorder. Mol Psychiatry. (2021) 26:5112–23. doi: 10.1038/s41380-020-0808-3
12. Czarny P, Białek K, Ziółkowska S, Strycharz J, Barszczewska G, Sliwinski T. The importance of epigenetics in diagnostics and treatment of major depressive disorder. J personalized Med. (2021) 11:167. doi: 10.3390/jpm11030167
13. Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. (2016) 17:47–62. doi: 10.1038/nrg.2015.10
14. Villegas VE, Zaphiropoulos P. Neighboring gene regulation by antisense long non-coding RNAs. Int J Mol Sci. (2015) 16:3251–66. doi: 10.3390/ijms16023251
15. Flynn Ryan A, Chang Howard Y. Long noncoding RNAs in cell-fate programming and reprogramming. Cell Stem Cell. (2014) 14:752–61. doi: 10.1016/j.stem.2014.05.014
16. Hosseini E, Bagheri-Hosseinabadi Z, De Toma I, Jafarisani M, Sadeghi I. The importance of long non-coding RNAs in neuropsychiatric disorders. Mol Aspects Med. (2019) 70:127–40. doi: 10.1016/j.mam.2019.07.004
17. Wu P, Zuo X, Deng H, Liu X, Liu L, Ji A. Roles of long noncoding RNAs in brain development, functional diversification and neurodegenerative diseases. Brain Res Bull. (2013) 97:69–80. doi: 10.1016/j.brainresbull.2013.06.001
18. Tsagakis I, Douka K, Birds I. Long non-coding RNAs in development and disease: Conservation to mechanisms. J Of Pathol. (2020) 250:480–95. doi: 10.1002/path.v250.5
19. Roy B, Wang Q, Dwivedi Y. Long noncoding RNA-associated transcriptomic changes in Resiliency or susceptibility to depression and response to antidepressant treatment. Int J Neuropsychopharmacol. (2018) 21:461–72. doi: 10.1093/ijnp/pyy010
20. Huang X, Luo Y-L, Mao Y-S, Ji J-L. The link between long noncoding RNAs and depression. Prog Neuro-Psychopharmacol. Biol Psychiatry. (2017) 73:73–8. doi: 10.1016/j.pnpbp.2016.06.004
21. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta stone of a hidden RNA language? Cell. (2011) 146:353–8. doi: 10.1016/j.cell.2011.07.014
22. Zhang Y, Xu Y, Feng L, Li F, Sun Z, Wu T, et al. Comprehensive characterization of lncRNA-mRNA related ceRNA network across 12 major cancers. Oncotarget. (2016) 7:64148–67. doi: 10.18632/oncotarget.11637
23. Chen Y, Lin Y, Bai Y, Cheng D, Bi Z. A long noncoding RNA (lncRNA)-associated competing endogenous RNA (ceRNA) network identifies eight lncRNA biomarkers in patients with osteoarthritis of the knee. Med Sci monitor: Int Med J Exp Clin Res. (2019) 25:2058–65. doi: 10.12659/MSM.915555
24. Yang F, Chen Y, Xue Z, Lv Y, Shen L, Li K, et al. High-throughput sequencing and exploration of the lncRNA-circRNA-miRNA-mRNA network in type 2 diabetes mellitus. BioMed Res Int. (2020) 8162524. doi: 10.1155/2020/8162524
25. Wang T, Xu S, Zhang H, Lu X, Li S, Liu L, et al. Competitive endogenous RNA network and pathway-based analysis of LncRNA single-nucleotide polymorphism in myasthenia gravis. Sci Rep. (2021) 11:23920. doi: 10.1038/s41598-021-03357-x
26. Barry G. Integrating the roles of long and small non-coding RNA in brain function and disease. Mol Psychiatry. (2014) 19:410–6. doi: 10.1038/mp.2013.196
27. Issler O, van der Zee YY, Ramakrishnan A, Wang J, Tan C, Loh Y-HE, et al. Sex-Specific role for the long non-coding RNA LINC00473 in depression. Neuron. (2020) 106:912–926.e915. doi: 10.1016/j.neuron.2020.03.023
28. Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. (2011) 9:90. doi: 10.1186/1741-7015-9-90
29. Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, et al. Gender differences in chronic major and double depression. J Affect Disord. (2000) 60:1–11. doi: 10.1016/S0165-0327(99)00158-5
30. Hastings RS, Parsey RV, Oquendo MA, Arango V, Mann JJ. Volumetric analysis of the prefrontal cortex, amygdala, and hippocampus in major depression. Neuropsychopharmacology. (2004) 29:952–9. doi: 10.1038/sj.npp.1300371
31. Khan A, Brodhead AE, Schwartz KA, Kolts RL, Brown WA. Sex differences in antidepressant response in recent antidepressant clinical trials. J Clin Psychopharmacol. (2005) 25:318–24. doi: 10.1097/01.jcp.0000168879.03169.ce
32. Labonté B, Engmann O, Purushothaman I, Menard C, Wang J, Tan C, et al. Sex-specific transcriptional signatures in human depression. Nat Med. (2017) 23:1102–11. doi: 10.1038/nm.4386
33. Zhou Y, Lutz P-E, Wang YC, Ragoussis J, Turecki G. Global long non-coding RNA expression in the rostral anterior cingulate cortex of depressed suicides. Trans Psychiatry. (2018) 8:224. doi: 10.1038/s41398-018-0267-7
34. Bu T, Qiao Z, Wang W, Yang X, Zhou J, Chen L, et al. Diagnostic biomarker hsa_circ_0126218 and functioning prediction in peripheral blood monocular cells of female patients with major depressive disorder. Front Cell Dev Biol. (2021) 9. doi: 10.3389/fcell.2021.651803
35. Arima T, Drewell R, Arney K, Inoue J, Makita Y, Hata A, et al. A conserved imprinting control region at the HYMAI/ZAC domain is implicated in transient neonatal diabetes mellitus. Hum Mol Genet. (2001) 10:1475–83. doi: 10.1093/hmg/10.14.1475
36. Arima T, Drewell R, Oshimura M, Wake N, Surani MA. A novel imprinted gene, HYMAI, is located within an imprinted domain on human chromosome 6 containing ZAC. Genomics. (2000) 67:248–55. doi: 10.1006/geno.2000.6266
37. Mackay D, Coupe AM, Shield J, Storr J, Temple I, Robinson D. Relaxation of imprinted expression of ZAC and HYMAI in a patient with transient neonatal diabetes mellitus. Hum Genet. (2002) 110:139–44. doi: 10.1007/s00439-001-0671-5
38. Iglesias-Platas I, Martin-Trujillo A, Cirillo D, Court F, Guillaumet-Adkins A, Camprubi C, et al. Characterization of novel paternal ncRNAs at the Plagl1 locus, including Hymai, predicted to interact with regulators of active chromatin. PLoS One. (2012) 7:e38907. doi: 10.1371/journal.pone.0038907
39. Bosire C, Vidal A, Smith J, Jima D, Huang Z, Skaar D, et al. Association between PEG3 DNA methylation and high-grade cervical intraepithelial neoplasia. Infect Agents Cancer. (2021) 16:42. doi: 10.1186/s13027-021-00382-3
40. Ryan JC, Wu Q, Shoemaker RC. Transcriptomic signatures in whole blood of patients who acquire a chronic inflammatory response syndrome (CIRS) following an exposure to the marine toxin ciguatoxin. BMC Med Genomics. (2015) 8:15. doi: 10.1186/s12920-015-0089-x
41. Moreau PR, Örd T, Downes NL, Niskanen H, Bouvy-Liivrand M, Aavik E, et al. Transcriptional profiling of hypoxia-regulated non-coding RNAs in human primary endothelial cells. Front Cardiovasc Med. (2018) 5:159. doi: 10.3389/fcvm.2018.00159
42. Gu S, Zi J, Han Q, Song C, Ge Z. The autophagy-related long non-coding RNA signature for acute myeloid leukemia. SSRN Electronic J. (2020). doi: 10.2139/ssrn.3578746
43. Liu H, Ye T, Yang X, Lv P, Wu X, Zhou H, et al. A panel of four-lncRNA signature as a potential biomarker for predicting survival in clear cell renal cell carcinoma. J Cancer. (2020) 11:4274–83. doi: 10.7150/jca.40421
44. Brintzenhofe-Szoc KM, Levin TT, Li Y, Kissane DW, Zabora JR. Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type. Psychosomatics. (2009) 50:383–91. doi: 10.1176/appi.psy.50.4.383
45. Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. (2011) 12:160–74. doi: 10.1016/S1470-2045(11)70002-X
46. Wang S, Tian M, Yang R, Jing Y, Chen W, Wang J, et al. 6-Gingerol ameliorates behavioral changes and atherosclerotic lesions in ApoE–/– mice exposed to chronic mild stress. Cardiovasc Toxicol. (2018) 18:420–30. doi: 10.1007/s12012-018-9452-4
47. de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: A meta-analysis. Psychosomatic Med. (2001) 63:619–30. doi: 10.1097/00006842-200107000-00015
48. Cao J, Yuan B, Guo P, Zhu H, Huang Z, He Y, et al. The influence of depression degree on regulatory T cells in patients with non-M3 acute myeloid leukemia. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. (2016) 37:1033–7.
49. Papiez MA, Dybala M, Sowa-Kucma M, Krzysciak W, Taha H, Jozkowicz A, et al. Evaluation of oxidative status and depression-like responses in Brown Norway rats with acute myeloid leukemia. Prog Neuropsychopharmacol Biol Psychiatry. (2009) 33:596–604. doi: 10.1016/j.pnpbp.2009.02.015
50. Dodd S, Pereira D, Buscher I, Andrasik M, Rose R, Simon T, et al. Relations between depressive symptoms and cervical dysplasia in HIV+ women with human papillomavirus (HPV) infection. Brain Behavior Immun. (2006) 20:14–5. doi: 10.1016/j.bbi.2006.04.028
51. Jonas R, Crabtree T, Jennings R, Choi A, Earls J, Min J. Cleerly: Relationship of diabetes to atherosclerotic plaque characteristics of coronary artery lesions by differing angiographic stenosis severity. Eur Heart J. (2021) 42. doi: 10.1093/eurheartj/ehab724.0164
52. Wan Y, Liu Y, Wang X, Wu J, Liu K, Zhou J, et al. Identification of differential microRNAs in cerebrospinal fluid and serum of patients with major depressive disorder. PLoS One. (2015) 10:e0121975. doi: 10.1371/journal.pone.0121975
53. Feng J, Wang M, Li M, Yang J, Jia J, Liu L, et al. Serum miR-221-3p as a new potential biomarker for depressed mood in perioperative patients. Brain Res. (2019) 1720:146296. doi: 10.1016/j.brainres.2019.06.015
54. Wei Z-X, Xie G-J, Mao X, Zou X-P, Liao Y-J, Liu Q-S, et al. Exosomes from patients with major depression cause depressive-like behaviors in mice with involvement of miR-139-5p-regulated neurogenesis. Neuropsychopharmacology. (2020) 45:1050–8. doi: 10.1038/s41386-020-0622-2
55. Liang JQ, Liao HR, Xu CX, Li XL, Wei ZX, Xie GJ, et al. Serum exosome-derived miR-139-5p as a potential biomarker for major depressive disorder. Neuropsychiatr Dis Treat. (2020) 16:2689–93. doi: 10.2147/NDT.S277392
56. Camkurt MA, Acar Ş, Coşkun S, Güneş M, Güneş S, Yılmaz MF, et al. Comparison of plasma MicroRNA levels in drug naive, first episode depressed patients and healthy controls. J Psychiatr Res. (2015) 69:67–71. doi: 10.1016/j.jpsychires.2015.07.023
57. Ferrúa CP, Giorgi R, da Rosa LC, do Amaral CC, Ghisleni GC, Pinheiro RT, et al. MicroRNAs expressed in depression and their associated pathways: A systematic review and a bioinformatics analysis. J Chem Neuroanat. (2019) 100:101650. doi: 10.1016/j.jchemneu.2019.101650
58. Duman RS, Li N, Liu RJ, Duric V, Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology. (2012) 62:35–41. doi: 10.1016/j.neuropharm.2011.08.044
59. Goswami DB, Jernigan CS, Chandran A, Iyo AH, May WL, Austin MC, et al. Gene expression analysis of novel genes in the prefrontal cortex of major depressive disorder subjects. Prog Neuropsychopharmacol Biol Psychiatry. (2013) 43:126–33. doi: 10.1016/j.pnpbp.2012.12.010
60. Jernigan CS, Goswami DB, Austin MC, Iyo AH, Chandran A, Stockmeier CA, et al. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. (2011) 35:1774–9. doi: 10.1016/j.pnpbp.2011.05.010
61. Marsden WN. Synaptic plasticity in depression: molecular, cellular and functional correlates. Prog Neuropsychopharmacol Biol Psychiatry. (2013) 43:168–84. doi: 10.1016/j.pnpbp.2012.12.012
62. Wang XL, Yuan K, Zhang W, Li SX, Gao GF, Lu L. Regulation of circadian genes by the MAPK pathway: implications for rapid antidepressant action. Neurosci Bull. (2020) 36:66–76. doi: 10.1007/s12264-019-00358-9
63. Qi X, Lin W, Wang D, Pan Y, Wang W, Sun M. A role for the extracellular signal-regulated kinase signal pathway in depressive-like behavior. Behav Brain Res. (2009) 199:203–9. doi: 10.1016/j.bbr.2008.11.051
64. Wang CJ, Zhang ZJ, Xu Z, Shi YY, Pu MJ, Zheng Z, et al. Kinase gene haplotypes and gene-gene interactions in the Ras-Raf-MAPK signaling pathway: association with antidepressant remission. Int Clin Psychopharmacol. (2013) 28:245–54. doi: 10.1097/YIC.0b013e328362c89f
65. De Ferrari GV, Moon RT. The ups and downs of Wnt signaling in prevalent neurological disorders. Oncogene. (2006) 25:7545–53. doi: 10.1038/sj.onc.1210064
66. Inestrosa NC, Arenas E. Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci. (2010) 11:77–86. doi: 10.1038/nrn2755
67. Tayyab M, Shahi MH, Farheen S, Mariyath MPM, Khanam N, Castresana JS, et al. Sonic hedgehog, Wnt, and brain-derived neurotrophic factor cell signaling pathway crosstalk: potential therapy for depression. J Neurosci Res. (2018) 96:53–62. doi: 10.1002/jnr.24104
68. Voleti B, Duman R. The roles of neurotrophic factor and Wnt signaling in depression. Clin Pharmacol Ther. (2011) 91:333–8. doi: 10.1038/clpt.2011.296
69. Okamoto H, Voleti B, Banasr M, Sarhan M, Duric V, Girgenti MJ, et al. Wnt2 expression and signaling is increased by different classes of antidepressant treatments. Biol Psychiatry. (2010) 68:521–7. doi: 10.1016/j.biopsych.2010.04.023
70. Adriaanse MC, Dekker JM, Nijpels G, Heine RJ, Snoek FJ, Pouwer F. Associations between depressive symptoms and insulin resistance: the Hoorn Study. Diabetologia. (2006) 49:2874–7. doi: 10.1007/s00125-006-0500-4
71. Kan C, Silva N, Golden S, Rajala U, Timonen M, Stahl D, et al. A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care. (2013) 36:480–9. doi: 10.2337/dc12-1442
72. Watson K, Nasca C, Aasly L, McEwen B, Rasgon N. Insulin resistance, an unmasked culprit in depressive disorders: Promises for interventions. Neuropharmacology. (2018) 136:327–34. doi: 10.1016/j.neuropharm.2017.11.038
73. Roy B, Dunbar M, Agrawal J, McKibben L, Dwivedi Y. Amygdala-Based Altered miRNome and Epigenetic Contribution of miR-128-3p in Conferring Susceptibility to Depression-Like Behavior via Wnt Signaling. Int J Neuropsychopharmacol. (2020) 23:165–77. doi: 10.1093/ijnp/pyz071
74. Biernacka J, Frye M. Pharmacogenomics of antidepressant induced mania. Eur Neuropsychopharmacol. (2017) 27:S512. doi: 10.1016/j.euroneuro.2016.09.623
75. Wang JW, Stifani S. Roles of runx genes in nervous system development. Adv Exp Med Biol. (2017) 962:103–16. doi: 10.1007/978-981-10-3233-2_8
76. Wuchty S, Myers AJ, Ramirez-Restrepo M, Huentelman M, Richolt R, Gould F, et al. Integration of peripheral transcriptomics, genomics, and interactomics following trauma identifies causal genes for symptoms of post-traumatic stress and major depression. Mol Psychiatry. (2021) 26:3077–92. doi: 10.1038/s41380-021-01084-3
Keywords: major depressive disorder, lncRNA, diagnostic biomarker, high throughput sequencing, bioinformatics analysis, peripheral blood mononuclear cells
Citation: Bu T, Yang J, Zhou J, Liu Y, Qiao K, Wang Y, Zhang J, Zhao E, Owura BK, Qiu X, Qiao Z and Yang Y (2025) LncRNA of peripheral blood mononuclear cells: HYMAI acts as a potential diagnostic and therapeutic biomarker for female major depressive disorder. Front. Psychiatry 16:1241089. doi: 10.3389/fpsyt.2025.1241089
Received: 17 July 2023; Accepted: 21 January 2025;
Published: 27 February 2025.
Edited by:
Francisco Navarrete Rueda, Miguel Hernández University of Elche, SpainReviewed by:
Lorenz S. Neuwirth, State University of New York at Old Westbury, United StatesYan Kong, Southeast University, China
Copyright © 2025 Bu, Yang, Zhou, Liu, Qiao, Wang, Zhang, Zhao, Owura, Qiu, Qiao and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yanjie Yang, eWFuamllMTk2NUAxNjMuY29t; Zhengxue Qiao, ODM1NzE1NjBAcXEuY29t; Xiaohui Qiu, cWl1eGFpb2h1aUBmb3htaWFsLmNvbQ==
†These authors have contributed equally to this work and share first authorship